Scientific Program

Conference Series Ltd invites all the participants across the globe to attend International Conference on Diabetes and its Complications Osaka, Japan.

Day 2 :

Keynote Forum

Eda Cengiz

Yale School of Medicine, USA

Keynote: New Era in Diabetes Management: Artificial Pancreas Systems and Beyond

Time : 09:30 - 10:00

OMICS International  Diabetic Complications 2018 International Conference Keynote Speaker Eda Cengiz photo
Biography:

 
Dr. Cengiz is an associate professor at Yale School of Medicine, division of Pediatric Endocrinology and a visiting professor at KOC School of Medicine. She has carried out various diabetes-related clinical studies focusing on insulin action (pharmacokinetics and pharmacodynamics), diabetes technology (continuous glucose sensors and insulin pumps), and artificial pancreas (closed-loop) systems in people with T1D as a principal investigator or co-investigator. She has conducted clinical studies in collaboration with investigators from centers of excellence in diabetes care in the US and overseas and published various papers. Dr. Cengiz has been a reviewer and editorial board member of many scientific journals and meetings. She is the co-chair of the pharmacology sub-group of the National Institutes of Health Pediatric Diabetes Treatment Core Group. Dr. Cengiz collaborates with pediatric diabetologists overseas through national and international organizations to promote the well-being of children with diabetes globally.
 

Abstract:

 
 The incorporation of new technology into diabetes treatment provided diabetologists with additional tools like glucose sensors, smart insulin pumps, and the promise of closed loop insulin therapy (a.k.a the artificial pancreas project), a mechanical solution for diabetes management to restore near-physiologic glycemic control automatically. Such a system consists of three main elements: insulin delivery, continuous glucose sensing, and a controller or algorithm that, similar to the beta cell, regulates the proper amount of insulin delivery at the proper time. Advances in newer insulin formulations with improved pharmacokinetics (PK) and pharmacodynamics (PD) will galvanize closed loop insulin therapy systems and overcome challenges, such as late action of rapid acting insulins resulting in postprandial hyperglycemia. The Yale Pediatric Diabetes Center has been one of the main hubs of the artificial pancreas project and of research studies investigating the PK-PD of new insulin formulations. This talk will highlight the results of key studies in the field of diabetes technology including euglycemic clamp studies investigating the PK-PD of novel ultra fast acting insulins, the impact of innovative insulin delivery devices on insulin action, and the artificial pancreas project. It will discuss the barriers and limitations of this relatively nascent technology and solutions to overcome these challenges
 

Keynote Forum

Hsinlin Cheng

Harvard Medical School, USA

Keynote: Molecular Mechanisms of Diabetic Neuropathy: From Clinical Practice to Bench Studies

Time : 10:00 - 10:30

OMICS International  Diabetic Complications 2018 International Conference Keynote Speaker Hsinlin Cheng photo
Biography:

Dr. Hsinlin Thomas Cheng MD, PhD is the Director of Headache and Neuropathic Pain Unit, Massachusetts General Hospital and Assistant Professor of Harvard Medical School. He is board-certified in Neurology and Pain Management. His research interests include studying the molecular mechanisms of headache and neuropathic pain to establish new therapeutic equipments.

Abstract:

Diabetic neuropathy (DN) is one of the most prevalent complication from type 2 diabetes.  Up to 26 % of patients with diabetic neuropathy from type 2 diabetes report a significantly decreased quality of life caused by painful diabetic neuropathy (PDN).  The development of mechanism-specific treatments for PDN is in an urgent need. To determine the molecular mechanisms that mediate the development of PDN in patients with type 2 diabetes.  We collected skin biopsies from patients with PDN and performed novel biomarkers studies to examine intraepidermal nerve fibers (IENF).  Our results demonstrated increased biomarkers of neural regeneration (GAP43) and degeneration (axonal swelling) in patients with PDN compared to DN patients have no neuropathic pain.
To further establish the molecular signaling pathways that contribute to PDN, we used db/db mouse as a mouse model.  We examined the gene and protein expression of dorsal root ganglion neurons and concluded that nerve growth factor/Trk A/p38 signaling pathway is essential for the development of PDN in db/db mice.  This activation of this pathway leads to increased nociceptive nerve regeneration and proinflammatory cytokine-mediated inflammation in IENF.  We also detected reduced expression of interleukin (IL)-10, an anti-inflammatory cytokine during the period of PDN in db/db mice.  Exogenous IL-10 treatment significantly inhibited upregulation of, NGF, TNF-α, and reduced PDN in db/db mice.  In addition, the activation of Langerhans cells, the dendritic cells in the skin, during the period of PDN was reduced by IL-10 treatment in the hind paws of db/db mice. Our studies demonstrated the dysregulation of NGF-dependent cytokine-mediated inflammation contributes to the development PDN in type 2 diabetes.  Our results will lead to new therapies that target this pathway for treating PDN of type 2 diabetes.
 
 

Keynote Forum

Ciddi Veeresham

Kakatiya University, India

Keynote: Medicinal plants used for the management of diabetic complications

Time : 11:00 - 11:30

OMICS International  Diabetic Complications 2018 International Conference Keynote Speaker Ciddi Veeresham photo
Biography:

Ciddi Veeresham has completed his PhD at the age of  32 years from kakatiya university and postdoctoral studies from Cornell University, school of Biochemical engineering ithaca, NY USA. He is the Professor of Pharmacy at University college of Pharmaceutical Sciences, Kakatiya University, Warangal, India.. He has published more than 130 papers in reputed journals and has been serving as an editorial board member of repute.            

 

Abstract:

The inhibitory activities of extracts containing various classes of phytoconstituents such as terpenoid, phenolic and other miscellenious were studied. In vitro rat lens aldose reductase (RLAR) and rat kidney aldose reductase (RKAR) inhibitory activity of standardized extracts of Boswellia serrata (leaves), Lagerstroema. speciosa (leaves), Ocimum gratissimum (leaves), Syzygium cumin (fruits), Morus alba (leaves), Phyllanthus amarus (whole plant), Punia granatum (fruits) and Stevia rebaudiana (leaves), Cassia auriculata (flower), Saraca asoca (flower) Andrographis paniculata (aerial parts), Butea monosperma, Picrorhiza kurroa and Hibiscus rosa-sinensis at concentrations of 10, 50 and 100 µg/ml;  and their active constituents  boswellic acid, corosolic acid, ursolic acid, ellagic acid, morusin, phyllanthin, punicalagin and stevioside, procyanidin B1, leucocyanidin, andrographolide, butein, resveratrol and quercetin, each at concentrations of 1, 5 and 10 µg/ml were assayed spectrophotometrically. Among the tested extracts and compounds, standardized extract of O. gratissimum showed the highest activity, while the extract of P. kurroa and Hibiscus rosa-sinensis were the least active.
 
Among the tested pure compounds the RLAR inhibitory activity of corosolic acid, boswellic acid, ursolic acid and resveratrol were better than the rest. The above compounds with the potent inhibitory activity against RLAR were tested against human recombinant aldose reductase followed by the in vivo AR inhibitory activity in rats using galactosemic model by estimating the lens galactitol levels by using gas liquid chromatography.
Based on the above studies on the AR inhibitory activity, some of the potent compounds such as ursolic acid and resveratrol were studied for their effect on diabetic complications such as cataract and nephropathy. The compounds were tested for the in vitro anticataract activity in isolated cattle lens using organ culture technique in Krebs’ ringer buffer medium. The ability of the compounds to inhibit the glucose mediated induction of cataract was measured with respect to extent of opacity and formation of polyols in the lens.
Further to the above studies, resveratrol and ursolic acid were tested for their activity in diabetic nephropathy along with various biochemical parameters to elucidate the mechanism of action of the compounds.Thus an extensive research on various phytoconstituents for their potential in alleviating diabetic complications was carried out which might fulfill the unmet clinical need in the treatment of these complications.
 
 

Keynote Forum

Lorna Kwai Ping Suen

The Hong Kong Polytechnic University, Hong Kong

Keynote: Association of auricular reflective points and status of type 2 diabetes mellitus
OMICS International  Diabetic Complications 2018 International Conference Keynote Speaker Lorna Kwai Ping Suen photo
Biography:

Lorna Suen is an Associate Professor at the School of Nursing and the Director of the Squina International Centre for Infection Control. Her research interests include complementary and alternative medicine, sleep studies as well as infection control. She has published 90 scientific articles in international refereed journals, over 60 conference abstracts, and four book chapters. She has extensive experience in conducting randomized controlled trials using auriculotherapy in the clinical treatment of a number of chronic problems, including insomnia, low back pain, osteoarthritic knee, and uncontrolled hypertension. She is also interested in investigating the predictive value of auricular diagnosis and has recently completed several projects on identifying the relationship of auricular reflective points with the coronary heart disease, diabetes mellitus, lower urinary tract syndrome, and metabolic syndrome. She is the editorial board member of a number of international refereed journals and is frequently invited as a speaker at universities and international conferences and as a consultant in numerous non-profit organizations in Hong Kong.

Abstract:

The reflexive property of the ear can cause various physical attributes to appear on the auricle in the presence of bodily disorders. The association of auricular signals (presence or absence of discoloration, marks after pressing, tenderness, and electrical resistance) and diabetes mellitus (DM) should be further examined because auricular diagnosis is an objective, painless, and non-invasive method that provides rapid access to information. A matched case–control study on 282 subjects was conducted. Cases (n = 141) were defined as those diagnosed with type 2 DM (T2DM). Every subject in the case group was matched with the control by age and gender. Ear diagnosis was conducted by visual inspection, electrical conductivity, and tenderness testing. Results suggest that the tenderness and electrical conductivity of some auricular points, including “pancreas & gallbladder” “endocrine,” “kidney,” “lower tragus,” “heart,” and “eyes”, were associated with T2DM status in Chinese population. In the subgroup analyses, certain auricular signals were also associated with glycemic control, disease duration, and related complications. Auricular diagnosis could be considered as a screening method for vulnerable populations with T2DM risk. Thus, appropriate interventions can be implemented to prevent or delay the progression of T2DM.